References
- Borchmann P, Goergen H, Kobe C. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390:2790–2802.
- von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30:907–913.
- Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015;385:1418–1427.
- Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32:1188–1194.
- Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. New England J Med. 2015;372:1598–1607.
- Brockelmann PJ, Angelopoulou MK, Vassilakopoulos TP. Prognostic factors in Hodgkin lymphoma. Semin Hematol. 2016;53:155–164.
- Mauch P, Goodman R, Hellman S. The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer. 1978;42:1039–1045.
- Gobbi PG, Bassi E, Bergonzi M, et al. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. Hematol Oncol. 2012;30:194–199.
- Gobbi PG, Bergonzi M, Bassi E, et al. Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy. Hematol Oncol. 2013;31:151–155.
- Gobbi PG, Bergonzi M, Bassi E, et al. Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters. Oncol Rep. 2012;28:815–820.
- Gobbi PG, Ghirardelli ML, Solcia M, et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. J Clin Oncol. 2001;19:1388–1394.
- Specht L, Nordentoft AM, Cold S, et al. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer. 1988;61:1719–1727.
- Specht L, Lauritzen AF, Nordentoft AM, et al. Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin's disease. The Danish National Hodgkin Study Group. Cancer. 1990;65:2594–2601.
- Specht L, Pedersen-Bjergaard J. Hodgkin's disease: recent concepts in classification and treatment. Eur J Haematol Suppl. 1988;48:7–14.
- Specht L, Nissen NI, Walbom-Jørgensen S. Therapeutic implications of mediastinal involvement in advanced Hodgkin's disease. Scand J Haematol. 2009;35:166–173. Aug
- Specht L, Nissen NI. Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol. 1988;41:359–367.
- Bradley AJ, Carrington BM, Lawrance JAL, et al. Assessment and significance of mediastinal bulk in Hodgkin's disease: comparison between computed tomography and chest radiography. J Clin Oncol. 1999;17:2493–2498.
- Kriz J, Mueller RP, Mueller H, et al. Large mediastinal tumor mass as a prognostic factor in Hodgkin's lymphoma. Is the definition on the basis of a chest radiograph in the era of CT obsolete? Strahlenther Onkol. 2012;188:1020–1024.